BioXcel CEO exercises 219 RSUs into common stock
BioXcel Therapeutics, Inc. director and CEO Vimal Mehta reported updated equity holdings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BioXcel Therapeutics, Inc. director and CEO Vimal Mehta reported updated equity holdings. On June 15, 2026, he exercised 219 Restricted Stock Units (RSUs) at $0.00 per unit, receiving the same number of common shares and bringing his direct common stock holdings to 69,817 shares.
Following this transaction, Mehta also reported holding 1,313 RSUs directly. The filing lists indirect ownership of 480,343 common shares held by BioXcel LLC and 125 common shares held by his spouse. A footnote explains these indirect positions and states that Mehta disclaims beneficial ownership except to the extent of his pecuniary interest.
Insider Trade Summary
219 shares exercised/converted
Exercise
4 txns
Insider
Mehta Vimal
Role
CEO and President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 219 | $0.00 | $0.00 |
| Exercise | Common Stock | 219 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 1,313 contracts (Direct);
Common Stock — 69,817 shares (Direct);
Common Stock — 125 shares (Indirect, By Spouse);
Common Stock — 480,343 shares (Indirect, By BioXcel LLC)
Footnotes (3)
- F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F2. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
- F3. On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Key Figures
RSUs exercised: 219 units
Exercise price: $0.00 per share
Direct common shares after transaction: 69,817 shares
+5 more
8 metrics
RSUs exercised
219 units
Converted into common stock on June 15, 2026
Exercise price
$0.00 per share
Price for 219 RSUs exercised into common stock
Direct common shares after transaction
69,817 shares
Total common stock directly held following RSU exercise
RSUs outstanding after transaction
1,313 units
Restricted Stock Units remaining following 219-unit exercise
Indirect shares via BioXcel LLC
480,343 shares
Common stock held of record by BioXcel LLC
Indirect shares via spouse
125 shares
Common stock held by spouse
RSU grant size
3,500 units
RSUs granted on March 15, 2023
Quarterly vesting rate
6.25% of total RSUs
RSUs vest at each successive three-month period after first anniversary
Key Terms
Restricted Stock Unit, derivative security, beneficial owner, pecuniary interest, +1 more
5 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficial owner financial
"the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC."
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."
Section 16 regulatory
"This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Vimal Mehta report for BioXcel Therapeutics (BTAI)?
Vimal Mehta reported exercising 219 Restricted Stock Units (RSUs) into common stock at $0.00 per share. This derivative exercise increased his directly held common shares and updated his remaining RSU balance and indirect ownership positions in BioXcel Therapeutics.
What indirect BioXcel Therapeutics (BTAI) holdings are reported for Vimal Mehta?
The filing shows indirect ownership of 480,343 common shares held by BioXcel LLC and 125 common shares held by his spouse. A footnote states Mehta may be deemed a beneficial owner but disclaims beneficial ownership except for his pecuniary interest.
What are the terms of Vimal Mehta’s 3,500 RSU grant from BioXcel Therapeutics (BTAI)?
On March 15, 2023, Mehta was granted 3,500 RSUs. 25% vest on the first anniversary of March 15, 2023, and 6.25% of the total number vest at the end of each successive three-month period, subject to continued employment.
How many RSUs remain for Vimal Mehta after the 219-unit exercise at BioXcel Therapeutics (BTAI)?
Following the 219-unit RSU exercise, the filing reports Mehta holding 1,313 Restricted Stock Units. Each RSU represents a contingent right to receive one share of BioXcel Therapeutics common stock, according to the explanatory footnote in the document.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates